Main Article Content
Urinary tract infections (UTIs) are the most prevalent type of nosocomial infection, and K. pneumoniae is the second most frequent Gram-negative bacterium cause of UTIs. A major worldwide health worry is the emergence of bacterial pathogens that are immune to numerous medications. Antibiotic overuse has limited our options for treating K. pneumoniae and made effective control of this bacterial disease more difficult..
For this study, we tested all Klebsiella pneumonia isolates for resistance to 17 antibiotics from various classes. We found that 83% of the isolates were resistant to the class polymyxin antibiotic (colistin), followed by 81% to ampicillin, and 80% to cephalosporin class antibiotics (cefotaxime, ceftriaxone) (57.5 percent ). About half of the bacteria tested were resistant to ceftazidime, 40% were resistant to tetracyclines, and 37% were resistant to macrolides like azithromycin (37,5) Comparatively few strains are resistant to the quinolones levofloxacin and ciprofloxacin (7.5%) or the pipracilline family (3%), an aminoglycoside (5%), or a tobramycin (5%). Antibiotics like gentamicin (an aminoglycoside), carbapenem (imipenem), and quinolone (naldixic acid) (10 percent)
16S rRNA confirms the molecular identification of k pneumonia isolates. Utilizing the NanoDrop instrument, the concentration and purity were determined. Purity was between 1.6 and 2.0, while concentration ranged from 50 to 360 ng/l. The AcrAB gene, with a molecular weight of 312bp, was detected using multiplex-PCR, and the findings indicated that all of the isolates tested positive for its presence. Molecular weight 1250 bp rmpA gene was found in 25% of the isolates, 226 bp mrkD gene gave 70% positive results, and rcsA and rcsB genes were found in 35%, 35%, and 95% of the isolates, respectively.